No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.
www.rpglifesciences.comNo one on the platform currently holds RPGLIFE.NS.
No tracked institution reports a position in RPGLIFE.NS as of their last filing.
No one on the platform has traded RPGLIFE.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.8% | 27.9% | 20.4% | — | — | — |
| Rev. Growth % | 8.3% | 13.0% | ||||
| Profit Margin % | 16.3% | 16.9% | 11.7% | |||
| Free Cash Flow Margin % | -0.0% | 6.3% | 4.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $3.5B | +14.7% | $14.94 | $14.94–$14.94 | — | 1 |
| 2028 | $4.2B | +20.8% | $23.68 | $23.68–$23.68 | — | 1 |
| 2029 | $3.7B | -12.2% | $19.61 | $19.61–$19.61 | — | 1 |
| 2030 | $4.1B | +11.7% | $22.69 | $22.69–$22.69 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-27 | $4.46 | $18.08 | +305.4% |
| 2026-01-22 | $3.87 | $13.38 | +245.7% |
| 2025-11-05 | $3.87 | $22.28 | +475.7% |
| 2025-07-25 | $3.87 | $15.90 | +310.9% |
| 2025-04-28 | $4.46 | $70.96 | +1491.0% |
| 2025-01-24 | $3.87 | $21.12 | +445.7% |
| 2024-11-07 | $3.87 | $2.54 | -34.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| RPGLIFE.NSRPG Life Sciences Limited | $2718.80 | +0.75% | $45.0B | — |
| AARTIDRUGS.BOAarti Drugs Limited | $426.85 | -0.32% | $39.0B | — |
| AARTIDRUGS.NSAarti Drugs Limited | $426.35 | -0.50% | $38.9B | — |
| INNOVACAP.NSInnova Captab Limited | $1140.10 | -0.62% | $65.2B | — |
| ORCHPHARMA.NSOrchid Pharma Limited |
| $988.20 |
| -1.48% |
| $50.1B |
| — |
| SHILPAMED.BOShilpa Medicare Limited | $911.85 | -5.31% | $89.2B | — |
| SPARC.NSSun Pharma Advanced Research Company Limited | $188.00 | -4.09% | $61.0B | — |
Source: Financial Modeling Prep · peers by sector/industry